PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more
PCI Biotech Holding ASA (PCIB) - Total Liabilities
Latest total liabilities as of June 2025: Nkr6.01 Million NOK
Based on the latest financial reports, PCI Biotech Holding ASA (PCIB) has total liabilities worth Nkr6.01 Million NOK as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PCI Biotech Holding ASA - Total Liabilities Trend (2008–2024)
This chart illustrates how PCI Biotech Holding ASA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PCI Biotech Holding ASA Competitors by Total Liabilities
The table below lists competitors of PCI Biotech Holding ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
US BANCORP (UB5.SG)
STU:UB5
|
Germany | €627.15 Billion |
|
DigiMax Global Inc
PINK:DBKSF
|
USA | $34.21 Million |
|
Sentient Brands Holdings Inc
NASDAQ:SNBHD
|
USA | $4.21 Million |
|
Canadian Spirit Resources Inc
PINK:CSPUF
|
USA | $1.83 Million |
|
ELISA - Dusseldorf Stock Exchang
DU:EIA
|
Germany | €1.98 Billion |
|
SUN HYDRAULICS
BE:SH7
|
Germany | €686.20 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down PCI Biotech Holding ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.27 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PCI Biotech Holding ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PCI Biotech Holding ASA (2008–2024)
The table below shows the annual total liabilities of PCI Biotech Holding ASA from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr7.76 Million | +55.02% |
| 2023-12-31 | Nkr5.01 Million | -17.63% |
| 2022-12-31 | Nkr6.08 Million | -72.60% |
| 2021-12-31 | Nkr22.19 Million | +11.61% |
| 2020-12-31 | Nkr19.88 Million | -26.93% |
| 2019-12-31 | Nkr27.20 Million | +59.07% |
| 2018-12-31 | Nkr17.10 Million | +3.06% |
| 2017-12-31 | Nkr16.59 Million | +78.20% |
| 2016-12-31 | Nkr9.31 Million | -23.14% |
| 2015-12-31 | Nkr12.12 Million | +7.52% |
| 2014-12-31 | Nkr11.27 Million | +20.64% |
| 2013-12-31 | Nkr9.34 Million | +9.95% |
| 2012-12-31 | Nkr8.49 Million | +11.31% |
| 2011-12-31 | Nkr7.63 Million | -16.30% |
| 2010-12-31 | Nkr9.12 Million | +41.32% |
| 2009-12-31 | Nkr6.45 Million | +22.31% |
| 2008-12-31 | Nkr5.28 Million | -- |